Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

TLR3 absence confers increased survival with improved macrophage activity against pneumonia
Madathilparambil V. Suresh, Vladislav A. Dolgachev, Boya Zhang, Sanjay Balijepalli, Samantha Swamy, Jashitha Mooliyil, Georgia Kralovich, Bivin Thomas, David Machado-Aranda, Monita Karmakar, Sanjeev Lalwani, Arulselvi Subramanian, Arun Anantharam, Bethany B. Moore, Krishnan Raghavendran
Madathilparambil V. Suresh, Vladislav A. Dolgachev, Boya Zhang, Sanjay Balijepalli, Samantha Swamy, Jashitha Mooliyil, Georgia Kralovich, Bivin Thomas, David Machado-Aranda, Monita Karmakar, Sanjeev Lalwani, Arulselvi Subramanian, Arun Anantharam, Bethany B. Moore, Krishnan Raghavendran
View: Text | PDF
Research Article Infectious disease

TLR3 absence confers increased survival with improved macrophage activity against pneumonia

  • Text
  • PDF
Abstract

Toll-like receptor 3 (TLR3) is a pathogen recognition molecule associated with viral infection with double-stranded RNA (dsRNA) as its ligand. We evaluated the role of TLR3 in bacterial pneumonia using Klebsiella pneumoniae (KP). WT and TLR3–/– mice were subjected to a lethal model of KP. Alveolar macrophage polarization, bactericidal activity, and phagocytic capacity were compared. RNA-sequencing was performed on alveolar macrophages from the WT and TLR3–/– mice. Adoptive transfers of alveolar macrophages from TLR3–/– mice to WT mice with KP were evaluated for survival. Expression of TLR3 in postmortem human lung samples from patients who died from gram-negative pneumonia and pathological grading of pneumonitis was determined. Mortality was significantly lower in TLR3–/–, and survival improved in WT mice following antibody neutralization of TLR3 and with TLR3/dsRNA complex inhibitor. Alveolar macrophages from TLR3–/– mice demonstrated increased bactericidal and phagocytic capacity. RNA-sequencing showed an increased production of chemokines in TLR3–/– mice. Adoptive transfer of alveolar macrophages from the TLR3–/– mice restored the survival in WT mice. Human lung samples demonstrated a good correlation between the grade of pneumonitis and TLR3 expression. These data represent a paradigm shift in understanding the mechanistic role of TLR3 in bacterial pneumonia.

Authors

Madathilparambil V. Suresh, Vladislav A. Dolgachev, Boya Zhang, Sanjay Balijepalli, Samantha Swamy, Jashitha Mooliyil, Georgia Kralovich, Bivin Thomas, David Machado-Aranda, Monita Karmakar, Sanjeev Lalwani, Arulselvi Subramanian, Arun Anantharam, Bethany B. Moore, Krishnan Raghavendran

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts